Pyrimido Aromatic Ring Compounds for Selective TLR8 Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new TLR8 agonists with high selectivity for the treatment and/or prevention of hepatitis B virus, as existing dual agonists of TLR8 and TLR7 do not fully address the therapeutic potential of TLR8 agonists.
Innovation Solution
Development of novel pyrimido aromatic ring compounds that selectively activate TLR8, offering good activating effects on TLR8 while minimizing induction or inhibition of liver drug enzymes and toxicity to the heart, and possessing good solubility, stability, and pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If dual agonists of TLR8 and TLR7 are used, then broad immune activation is achieved, but selectivity for TLR8 is reduced
Solution Approach 1:
The patent segments the TLR agonist function by designing compounds that selectively target TLR8 without activating TLR7, separating the immune activation function from off-target effects. This is achieved through specific molecular structure design (Formula I compounds) that exhibit preferential binding to TLR8
Solution Approach 2:
The patent applies local quality by modifying specific regions of the molecule (substituents at different positions of the pyrimido aromatic ring structure) to enhance TLR8 selectivity while maintaining immune activation capability. Different substituent patterns (R1-R9 groups) create localized interactions that favor TLR8 binding
2Reliability
If TLR8 agonist activity is enhanced, then therapeutic effect against HBV is improved, but liver drug enzyme induction or inhibition may increase
Solution Approach 1:
The patent converts the potential harm of liver enzyme interactions by designing compounds that minimize these interactions while maintaining TLR8 agonist activity. The molecular structure is optimized to avoid metabolism through major liver drug enzymes, transforming a potential liability into a safety advantage
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular properties (substituent types, positions, and configurations) to optimize the balance between TLR8 activation potency and liver enzyme interaction profile, achieving compounds with favorable pharmacokinetic and safety characteristics
3Power
If TLR8 agonist potency is increased, then immune response activation is enhanced, but cardiac toxicity may increase
Solution Approach 1:
The patent extracts the harmful cardiac toxicity aspect from the TLR8 agonist profile by designing compounds that achieve potent immune activation through alternative mechanisms that do not trigger cardiac adverse effects. The molecular structure is specifically designed to avoid cardiac cell toxicity while maintaining immunomodulatory activity
4Measurement precision
If molecular structure is optimized for TLR8 selectivity, then therapeutic specificity is improved, but solubility and stability may be compromised
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular properties (adding polar groups, adjusting aromatic ring substitutions, modifying side chains) to achieve the optimal balance between TLR8 selectivity, solubility, and stability. Different substituent patterns are evaluated to find the sweet spot for all three parameters
Data Source
AI summary
A pyrimido aromatic ring compound and a use thereof in a drug, especially a use thereof as a TLR8 agonist. Specifically, the compound is represented by general formula (I), or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof, and a use thereof as a drug, especially a use thereofas the TLR8 agonist.